Home  |  Contact

Cellosaurus Mahlavu (CVCL_0405)

[Text version]

Cell line name Mahlavu
Synonyms MAHLAVU
Accession CVCL_0405
Resource Identification Initiative To cite this cell line use: Mahlavu (RRID:CVCL_0405)
Comments Part of: Liver Cancer Model Repository (LIMORE).
Population: African.
Doubling time: 22.5 hours (CelloPub=CLPUB00076); 52.01 hours (PubMed=31378681).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: Genome sequenced.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Misspelling: Malhavu; Occasionally.
Derived from sampling site: Liver.
Sequence variations
Disease Hepatocellular carcinoma (NCIt: C3099)
Hepatocellular carcinoma (ORDO: Orphanet_88673)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): PubMed=31378681

Markers:
AmelogeninX
CSF1PO7,11
D5S81812
D7S82010,11
D13S31712,13
D16S53911
TH017
TPOX8,10
vWA15

Run an STR similarity search on this cell line
Web pages https://lccl.zucmanlab.com/hcc/cellLines/Mahlavu
Publications

CLPUB00076
Prozesky O.W., Brits C., Grabow W.O.K.
In vitro culture of cell lines from Australia antigen positive and negative hepatoma patients.
(In) Liver; Saunders S.J., Terblanche J. (eds.); pp.358-360; Pitman Medical Books; London (1973)

CLPUB00575
Prozesky O.W., Lecatsas G.
Scanning electron microscopy of a human hepatoma cell line.
S. Afr. Med. J. 49:1061-1062(1975)

PubMed=179808; DOI=10.1111/j.1432-1033.1976.tb10294.x
Grimm J.
The influence of insulin on various enzyme activities in human and rat hepatoma cells.
Eur. J. Biochem. 64:249-253(1976)

PubMed=6268737; DOI=10.1099/0022-1317-53-1-105
Oefinger P.E., Bronson D.L., Dreesman G.R.
Induction of hepatitis B surface antigen in human hepatoma-derived cell lines.
J. Gen. Virol. 53:105-113(1981)

PubMed=6275024; DOI=10.1099/0022-1317-57-1-95
Koshy R., Maupas P., Muller R., Hofschneider P.H.
Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.
J. Gen. Virol. 57:95-102(1981)

DOI=10.1007/978-4-431-68349-0_4
Alexander J.J.
Human hepatoma cell lines.
(In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)

PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613
Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.
FASEB J. 7:1407-1413(1993)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x
Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.
HLA expression in hepatocellular carcinoma cell lines.
Clin. Exp. Immunol. 97:328-333(1994)

PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218.1-2218.7(2013)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)

PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001
Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Gastroenterology 157:760-776(2019)

PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001
Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.
A pharmacogenomic landscape in human liver cancers.
Cancer Cell 36:179-193.e11(2019)

Cross-references
Cell line databases/resources MCCL; MCC:0000299
LIMORE; Mahlavu
Anatomy/cell type resources BTO; BTO:0004471
Encyclopedic resources Wikidata; Q54903975
Gene expression databases GEO; GSM2551578
Polymorphism and mutation databases Cosmic; 873398
Cosmic; 948064
Cosmic; 979727
Cosmic; 1019317
Cosmic; 2162534
Cosmic; 2321039
IARC_TP53; 2183
Entry history
Entry creation04-Apr-2012
Last entry update16-Dec-2021
Version number20